摘要
目的探讨靶向组织因子(TF)的人源化抗体对结肠癌细胞杀伤和迁移作用。方法体外培养人源化TF抗体高表达CHO-5G4.1细胞,经蛋白A(Protein A)和凝胶层析柱纯化,利用毛细管SDS-PAGE检测抗体纯度,采用凝血酶原时间(PT)法测定抗凝血活性,采用抗体依赖细胞介导的细胞毒作用(ADCC)分析抗体对SW620和SW480结肠癌细胞的杀伤效应,Transwell^(TM)检测抗体对细胞迁移的影响,明胶酶谱和Western blot法检测人源化TF抗体处理后,迁移相关蛋白基质金属蛋白酶2(MMP2)、MMP9、黏着斑激酶(FAK)和磷酸化的FAK(p-FAK)蛋白水平的变化。结果通过两步法纯化人源化TF抗体毛细管SDS-PAGE检测纯度可达96.9%,并具有抗凝血活性。人源化TF抗体可通过ADCC杀死结肠癌细胞并明显抑制结肠癌细胞的迁移,抑制率达到99%,并可降低MMP2的表达及p-FAK的表达。结论获得了高纯度的人源化TF抗体,该抗体可通过ADCC杀伤结肠癌细胞,并可抑制FAK信号通路降低MMP2的表达,抑制结肠癌细胞的迁移。
Objective To investigate the killing effect of humanized antibodies targeting tissue factors on colon cancer cells as well as migration-inhibiting effect.Methods Humanized anti-tissue factor antibody was purified by Protein A and gel filtration chromatography from cultured CHO-5G4.1 cells that highly express the antibody.The purity was detected by capillary SDS-PAGE.Anticoagulant activity was assessed using the prothrombin time test.Killing effect of the antibody on SW620 and SW480 colorectal cancer cells was tested using antibody-dependent cell-mediated cytotoxicity(ADCC).The effect of antibodies on cell migration was investigated using Transwell^(TM)assay.Gelatin zymography and Western blotting were used to detect the changes of matrix metalloproteinase 2(MMP2),MMP9,focal adhesion kinase(FAK)and phosphorylated FAK(p-FAK)after treatment with humanized anti-tissue factor antibody.Results The purity of the humanized anti-tissue factor antibody was estimated 96.9%by the two-step method.The purified antibody showed an obvious anticoagulant activity.The antibody treatment had a significant killing effect on colorectal cancer cells through ADCC and a significant inhibiting effect(99%)on cell migration.The antibody significantly inhibited expression of MMP2 and p-FAK.Conclusion The humanized anti-tissue factor antibody can effectively kill tumor cells through ADCC and inhibit cancer cell migration,which is possibly mediated by MMP2 expression through suppression of FAK signaling.
作者
赵亚蕊
赵邑
赵峰梅
潘薇薇
张全爱
曹鹏程
梁欣欣
ZHAO Yarui;ZHAO Yi;ZHAO Fengmei;PAN Weiwei;ZHANG Quanai;CAO Pengcheng;LIANG Xinxin(Shanxi Biological Research lnstitute Co,Ld,Shanxi Key Laboratory of Pharmaceutical Biotechnology,Taiyuan 030006,China)
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2021年第2期168-173,共6页
Chinese Journal of Cellular and Molecular Immunology
基金
山西省应用基础研究项目(201701D221260)
山西省重点研发计划(201703D111031-2,201803D421007)。